PURPOSE: Adenosine kinase (ADK) represents the key metabolic enzyme for the regulation of extracellular adenosine levels in the brain. In adult brain, ADK is primarily present in astrocytes. Several lines of experimental evidence support a critical role of ADK in different types of brain injury associated with astrogliosis, which is also a prominent morphologic feature of temporal lobe epilepsy (TLE). We hypothesized that dysregulation of ADK is an ubiquitous pathologic hallmark of TLE. METHODS: Using immunocytochemistry and Western blot analysis, we investigated ADK protein expression in a rat model of TLE during epileptogenesis and the chronic epileptic phase and compared those findings with tissue resected from TLE patients with mesial temporal sclerosis (MTS). KEY FINDINGS: In rat control hippocampus and cortex, a low baseline expression of ADK was found with mainly nuclear localization. One week after the electrical induction of status epilepticus (SE), prominent up-regulation of ADK became evident in astrocytes with a characteristic cytoplasmic localization. This increase in ADK persisted at least for 3-4 months after SE in rats developing a progressive form of epilepsy. In line with the findings from the rat model, expression of astrocytic ADK was also found to be increased in the hippocampus and temporal cortex of patients with TLE. In addition, in vitro experiments in human astrocyte cultures showed that ADK expression was increased by several proinflammatory molecules (interleukin-1β and lipopolysaccharide). SIGNIFICANCE: These results suggest that dysregulation of ADK in astrocytes is a common pathologic hallmark of TLE. Moreover, in vitro data suggest the existence of an additional layer of modulatory crosstalk between the astrocyte-based adenosine cycle and inflammation. Whether this interaction also can play a role in vivo needs to be further investigated. Wiley Periodicals, Inc.
PURPOSE:Adenosine kinase (ADK) represents the key metabolic enzyme for the regulation of extracellular adenosine levels in the brain. In adult brain, ADK is primarily present in astrocytes. Several lines of experimental evidence support a critical role of ADK in different types of brain injury associated with astrogliosis, which is also a prominent morphologic feature of temporal lobe epilepsy (TLE). We hypothesized that dysregulation of ADK is an ubiquitous pathologic hallmark of TLE. METHODS: Using immunocytochemistry and Western blot analysis, we investigated ADK protein expression in a rat model of TLE during epileptogenesis and the chronic epileptic phase and compared those findings with tissue resected from TLEpatients with mesial temporal sclerosis (MTS). KEY FINDINGS: In rat control hippocampus and cortex, a low baseline expression of ADK was found with mainly nuclear localization. One week after the electrical induction of status epilepticus (SE), prominent up-regulation of ADK became evident in astrocytes with a characteristic cytoplasmic localization. This increase in ADK persisted at least for 3-4 months after SE in rats developing a progressive form of epilepsy. In line with the findings from the rat model, expression of astrocytic ADK was also found to be increased in the hippocampus and temporal cortex of patients with TLE. In addition, in vitro experiments in human astrocyte cultures showed that ADK expression was increased by several proinflammatory molecules (interleukin-1β and lipopolysaccharide). SIGNIFICANCE: These results suggest that dysregulation of ADK in astrocytes is a common pathologic hallmark of TLE. Moreover, in vitro data suggest the existence of an additional layer of modulatory crosstalk between the astrocyte-based adenosine cycle and inflammation. Whether this interaction also can play a role in vivo needs to be further investigated. Wiley Periodicals, Inc.
Authors: Ingmar Blümcke; Elisabeth Pauli; Hans Clusmann; Johannes Schramm; Albert Becker; Christian Elger; Martin Merschhemke; Heinz-Joachim Meencke; Thomas Lehmann; Andreas von Deimling; Christian Scheiwe; Josef Zentner; Benedikt Volk; Johann Romstöck; Hermann Stefan; Michelle Hildebrandt Journal: Acta Neuropathol Date: 2007-01-13 Impact factor: 17.088
Authors: Lori-An V Etherington; Graham E Patterson; Louise Meechan; Detlev Boison; Andrew J Irving; Nicholas Dale; Bruno G Frenguelli Journal: Neuropharmacology Date: 2008-10-10 Impact factor: 5.250
Authors: Matthew L Diamond; Anne C Ritter; Edwin K Jackson; Yvette P Conley; Patrick M Kochanek; Detlev Boison; Amy K Wagner Journal: Epilepsia Date: 2015-06-04 Impact factor: 5.864
Authors: Theresa A Lusardi; Kiran K Akula; Shayla Q Coffman; David N Ruskin; Susan A Masino; Detlev Boison Journal: Neuropharmacology Date: 2015-08-06 Impact factor: 5.250